BioTechniques is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Journal
    • Aims and scope
    • Journal archive
    • Editorial board
    • For authors
    • Your editors: what do we do?

    Follow us on social media

  • Current issue
  • News
    • Latest news
    • Tech news
    • Events news
    • Company news

    Follow us on social media

  • Multimedia
    • Downloadable eBooks
    • Infographics
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • Features
    • Interviews
    • Opinion
    • In Focus
    • Spotlights
    • Companies
    • New products
    • Events

    Follow us on social media

  • Topics
    • Analytical chemistry
      • Biochemistry
      • Bioengineering and biophysics
      • Cancer research
      • Careers and Publishing
      • Cell and tissue biology
      • COVID-19
      • CRISPR
      • Computational biology
    • Diagnostics and preclinical
      • Drug discovery and development
      • Immunology
      • Lab design and machinery
      • Microbiology
      • Molecular biology
    • Nanomedicine
      • Neuroscience
      • PCR and sequencing
      • Plant and climate science
      • Proteomics
      • Veterinary science
      • Whole-genome studies

    Follow us on social media

  • Become a member
Don't miss our upcoming webinar on 'Metagenomics for pathogen surveillance' REGISTER NOW!

Nanomedicine

Nanomedicine is the application of nanotechnology in medical applications, for example in the diagnosis and treatment of different diseases. It is a relatively new field of medicine, with only 72 scientific articles published on this topic up until 2004, and has since expanded significantly.

Read more...

Nanomedicine has the potential to impact many fields of medicine; however, further research is needed to identify any unwanted biological effects of these nanomaterials. Nanomaterials are around 1-100 nm, meaning they are suitable for targeted drug delivery pathways, which reduces the potential for side effects elsewhere in the human body. In vivo imaging is another potential application as nanoparticles have previously been used in imaging cardiovascular disease, for example.

For more information and research papers about the techniques involved in nanomedicine, read our peer-reviewed journal content here.

  • About BioTechniques
  • Advisory Board
  • Contact Us
  • Advertising
  • Permissions
  • Whitelist Emails
Contact
Contact Us
Office info

BioTechniques is powered by Taylor & Francis Group

BioTechniques, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom

Impact Factor 2.2 | CiteScore 2.0

  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 BioTechniques